The incidental postmenopausal adnexal mass

Clinical Obstetrics and Gynecology

Volumn 49, Issue 3, 2006, Pages 506-516

  McDonald, J Matt ^a   Modesitt, Susan C ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Asymptomatic; Cysts; Ovary; Postmenopausal; Ultrasound

Indexed keywords

CA 125 ANTIGEN;

ADNEXA DISEASE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; LABORATORY DIAGNOSIS; OVARY CANCER; OVARY CYST; POSTMENOPAUSE; PREDICTION; PREVALENCE; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; UTERUS CANCER;

CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; FEMALE; HUMANS; INCIDENCE; OVARIAN CYSTS; OVARIAN NEOPLASMS; POSTMENOPAUSE;

EID: 33746801602     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200609000-00010     Document Type: Review

References (25)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Ueland FR, DePriest PD, Pavlik EJ, et al. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol. 2003;91:46-50.
3. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003;102:594-599.
4. Pavlik EJ, Johnson TL II, Depriest PD, et al. Continuing participation supports ultrasound screening for ovarian cancer. Ultrasound Obstet Gynecol. 2000;15:354-364.
5. Bailey CL, Ueland FR, Land GL, et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol. 1998;69:3-7.
6. Wolf SI, Gosink BB, Feldesman MR, et al. Prevalence of simple adnexal cysts in postmenopausal women. Radiology. 1991;180:65-71.
7. Dorum A, Blom GP, Ekerhovd E, et al. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol. 2005;192:48-54.
8. Curtin JP. Management of the adnexal mass. Gynecol Oncol. 1994;55:S42-S46.
9. Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician. 1998;57:2471-2476,2479-2480
10. Bennington JL, Ferguson BR, Haber SL. Incidence and relative frequency of benign and malignant ovarian neoplasms. Obstet Gynecol. 1968;32:627-632.
11. Koonings PP, Campbell K, Mishell DR Jr, et al. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921-926.
12. Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol. 1989;35:139-144.
13. van Nagell JR, DePriest PD. Management of adnexal masses in postmenopausal women. Am J Obstet Gynecol. 2005;193:30-35.
14. Tekay A, Jouppila P. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand. 1996;75:316-329.
15. Marret H, Sauget S, Giraudeau B, et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med. 2004;23:1629-1639; quiz 1641-1642.
16. Alcazar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol. 2005;192:807-812.
17. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223:780-788.
18. Onyeka BA, Atalla A, Deemer H. Comparative diagnostic values of greyscale USS versus CT scan in the primary management of gynaecological pelvic mass with emphasis on ovarian cancer detection and staging. J Obstet Gynaecol. 2001;21:516-519.
19. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
20. Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988;159:341-346.
21. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003;21:206-210.
22. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
23. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst. 2005;97:315-319.
24. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:7677-7682.
25. Cohen CJ, Jennings TS. Screening for ovarian cancer: the role of noninvasive imaging techniques. Am J Obstet Gynecol. 1994;170:1088-1094.